🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

635 results for “dose” Clear

  1. A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    advanced, unresectable and/or metastatic solid tumors

    phase 1 other active

    1 trial

  2. A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas

    Boehringer Ingelheim

    colorectal carcinoma (CRC)

    phase 1 other active

    1 trial

  3. A study to test different doses of obrixtamig (BI 764532) in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.

    Boehringer Ingelheim

    Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

    phase 1 other active

    1 trial

  4. A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced solid tumours

    phase 1 other active

    1 trial

  5. A study to test how different doses of BI 3731579 are tolerated by healthy people

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  6. A study to test how different doses of BI 3814916 are tolerated by healthy people

    Boehringer Ingelheim

    healthy volunteer trial

    phase 1 other active

    1 trial

  7. A study to test how well different doses of BI 3031185 are tolerated by healthy men and women

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  8. A study to test how well different doses of BI 3034701 are tolerated by healthy men and people with overweight or obesity

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  9. A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH

    Boehringer Ingelheim

    Metabolic Dysfunction-associated Steatohepatitis

    phase 1 other active

    1 trial

  10. A study to test how well different doses of BI 3810477 are tolerated by healthy men

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  11. A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    phase 1 other active

    1 trial

  12. A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3

    Boehringer Ingelheim

    Glioma expressing DLL3

    phase 1 other active

    1 trial

  13. A study to test how well multiple doses of BI 3810477 are tolerated by healthy adults.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  14. A study to test how well multiple doses of BI 765423 are tolerated by healthy men

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  15. A study to test whether multiple doses of BI 456906 have an effect on cardiac safety in people with overweight or obesity.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  16. A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

    CureVac AG

    metastatic squamous non-small cell lung cancer

    phase 1 other active

    1 trial

  17. A trial to learn about how multiple doses of itraconazole change how AZD5004 moves throughout the body over time in healthy adults and how multiple doses of AZD5004 change how ethinyl estradiol and levonorgestrel move throughout the body overtime in healthy female adults

    AstraZeneca AB

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  18. A trial to learn how well different doses of andexanet alfa work and how they affect blood clotting throughout the body in healthy adults who have taken an FXa inhibitor

    AstraZeneca AB

    Healthy Volunteers

    phase 1 other active

    1 trial

  19. AKB-6548 (therapeutic dose)

    Akebia Europe Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. AN OPEN LABEL, TWO PERIODS, TWO SEQUENCES, CROSSOVER, RANDOMIZED MULTIPLE DOSE BIOEQUIVALENCE STUDY OF GUANFACINE 7 MG PROLONGED-RELEASE TABLETS (TEST FORMULATION) VS. EQUAL DOSE OF INTUNIV® PROLONGED-RELEASE TABLETS (REFERENCE FORMULATION) IN HEALTHY MALE VOLUNTEERS UNDER FASTING CONDITIONS

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Study performed on healthy volunteers.

    phase 1 other active

    1 trial

  21. AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    phase 1 other active

    1 trial

  22. APL-1202 and APL-1501 (Single ascending dose)

    Jian Li

    Bladder Cancer

    phase 1 small molecule active

    1 trial

  23. Ampreloxetine <Dose A>

    Theravance Biopharma Ireland Umited

    Symptomatic Neurogenic Orthostatic Hypertension

    phase 1 small molecule completed

    1 trial

  24. An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-77242113 in Adult Participants

    Janssen-Cilag International N.V.

    Renal Impairment

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources